Regeneron Pharmaceuticals (NASDAQ:REGN) Raised to “Buy” at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a hold rating to a buy rating in a research report report published on Friday, October 19th.

Several other equities research analysts have also recently weighed in on the company. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $409.00 to $412.00 and gave the stock an equal weight rating in a report on Thursday, October 11th. Canaccord Genuity boosted their price target on Regeneron Pharmaceuticals from $390.00 to $410.00 and gave the stock a hold rating in a research report on Thursday, October 11th. JPMorgan Chase & Co. reissued a hold rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, October 2nd. Leerink Swann boosted their price target on Regeneron Pharmaceuticals from $506.00 to $512.00 and gave the stock an outperform rating in a research report on Monday, October 1st. Finally, Cantor Fitzgerald began coverage on Regeneron Pharmaceuticals in a research report on Monday, October 1st. They issued a neutral rating and a $415.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and seven have given a buy rating to the company. Regeneron Pharmaceuticals currently has an average rating of Hold and an average target price of $410.95.

Shares of REGN stock traded down $6.68 during mid-day trading on Friday, hitting $356.66. The stock had a trading volume of 543,997 shares, compared to its average volume of 893,085. Regeneron Pharmaceuticals has a 12-month low of $281.89 and a 12-month high of $416.49. The stock has a market capitalization of $39.36 billion, a price-to-earnings ratio of 26.60, a P/E/G ratio of 1.22 and a beta of 1.34. The company has a current ratio of 4.04, a quick ratio of 2.92 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.94 by $0.93. Regeneron Pharmaceuticals had a return on equity of 30.24% and a net margin of 28.24%. The business had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.64 billion. During the same period in the prior year, the business earned $3.99 EPS. The business’s revenue for the quarter was up 10.8% compared to the same quarter last year. Research analysts predict that Regeneron Pharmaceuticals will post 19.31 EPS for the current fiscal year.

In other news, Director Joseph L. Goldstein sold 2,000 shares of the company’s stock in a transaction dated Monday, September 24th. The stock was sold at an average price of $388.65, for a total value of $777,300.00. Following the sale, the director now owns 13,000 shares in the company, valued at $5,052,450. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Sanofi sold 104,552 shares of the company’s stock in a transaction dated Thursday, September 6th. The stock was sold at an average price of $406.68, for a total value of $42,519,207.36. The disclosure for this sale can be found here. In the last quarter, insiders have sold 110,052 shares of company stock worth $44,651,762. Company insiders own 12.42% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP boosted its position in Regeneron Pharmaceuticals by 1.2% during the first quarter. Dimensional Fund Advisors LP now owns 169,670 shares of the biopharmaceutical company’s stock worth $58,428,000 after purchasing an additional 2,053 shares in the last quarter. Commonwealth Equity Services LLC boosted its position in Regeneron Pharmaceuticals by 8.1% during the first quarter. Commonwealth Equity Services LLC now owns 5,686 shares of the biopharmaceutical company’s stock worth $1,958,000 after purchasing an additional 427 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its position in Regeneron Pharmaceuticals by 5.1% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,868 shares of the biopharmaceutical company’s stock worth $1,331,000 after purchasing an additional 189 shares in the last quarter. LPL Financial LLC boosted its position in Regeneron Pharmaceuticals by 62.8% during the first quarter. LPL Financial LLC now owns 15,769 shares of the biopharmaceutical company’s stock worth $5,430,000 after purchasing an additional 6,080 shares in the last quarter. Finally, Legal & General Group Plc boosted its position in Regeneron Pharmaceuticals by 1.0% during the first quarter. Legal & General Group Plc now owns 364,977 shares of the biopharmaceutical company’s stock worth $125,667,000 after purchasing an additional 3,437 shares in the last quarter. Hedge funds and other institutional investors own 66.06% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More: Understanding Relative Strength Index

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.